Compare Incyte Corporation (INCY) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wendys Co — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Incyte Corporation is far larger — about 19.2× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Wendys Co for 77 Days on average.
| INCY | WEN | |
|---|---|---|
Market Cap | $22.85B | $1.19B |
Volume | 1,927,029 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $9.33 |
52-Week Low | $83.80 | $6.10 |
Typical Hold Time | 33 Days | 77 Days |
Enterprise Value | $18.35B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Wendy's stock trades at $6.23, up 1.96% today, but remains under significant pressure with a bearish technical outlook. The company faces declining same-store sales, a major franchisee bankruptcy, and net income margin compression from 7.58% in 2025 to 5.72% projected for 2026. Despite beating earnings expectations in recent quarters, valuation metrics appear attractive with P/E of 9.45 and P/S of 0.54, though high debt levels and competitive pressures persist.
The investment case hinges on new CEO Bob Wright's turnaround execution against substantial headwinds. While the stock trades at a discount to analyst consensus target of $7.58, near-term risks from franchisee instability and market share losses to burger chain competitors outweigh valuation appeal. Recovery depends on reversing sales trends and managing $2.66 billion in long-term debt effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
